Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ovid, Angelini Pharma Enter Exclusive License Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ovid, Angelini Pharma Enter Exclusive License Agreement

To develop, manufacture and commercialize OV101 for the treatment of Angelman Syndrome in Europe

By: Contract Pharma

Contract Pharma Staff

Ovid Therapeutics and Angelini Pharma S.p.A. have entered an agreement in which Angelini Pharma will develop, manufacture and commercialize OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the EU and other countries in the European Economic Area (Switzerland, Turkey and the United Kingdom) and Russia. Angelini Pharma will execute the agreement through its new affiliate Angelini Pharma Rare Diseases AG. OV101 is believed to be the only delta (δ)-selective GABAA receptor agonist in development and is currently being evaluated in the Phase III NEPTUNE trial in Angelman syndrome, with results expected in 4Q20.

Ovid will receive an upfront payment of $20 million and is eligible to receive up to an additional $212.5 million based on development, manufacturing and sales milestones, as well as royalties on sales if OV101 if successfully commercialized. Ovid will retain all U.S. and rest-of-world commercial rights to OV101.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics